Journal
CANCER LETTERS
Volume 457, Issue -, Pages 20-27Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.04.039
Keywords
Patient-derived organoid; Precision medicine; Preclinical model; 3D culture
Categories
Funding
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDA16020905, XDB19000000]
- National Key Research and Development Program of China [2017YFA0505500]
- National Natural Science Foundation of China [81830054, 81772723]
Ask authors/readers for more resources
Organoid technology has been remarkably improved over the last decade. Various organoids have been derived from different types of tissues and recapitulate their organ-specific gene expression signatures, particular tissue spatial structures and functions of their original tissue. The patient-derived organoids (PDOs) have been used to elucidate crucial scientific questions, including the relationships between genetic/epigenetic alterations and drug responses, cell plasticity during disease progressions, and mechanisms of drug resistances. With the great expectations, PDOs will be widely used to facilitate the personalized medical decisions, which have the potential to profoundly improve patient outcomes. In this review, we will discuss the developmental details, current achievements, applications and challenges of organoid technology in precision cancer medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available